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INTRODUCTION
The colloquial phrase that urges a consumer to “talk to [their] doctor about [insert drug
here]” is a hallmark of drug advertising.1 Television and print advertising are likely the most
common media sources where consumers are exposed to that phrase.2 However, consumers are
not exposed to these advertisements as aggressively on their social media platforms, but this is
changing.3 This is likely due to a lingering challenge the Food and Drug Administration (FDA)
has grappled with for direct-to-consumer (DTC) advertising of prescription drug products.4
However, consumers are active about their health and over half of the United States population

1

See, e.g., The Ambien Brand: Where Millions Have Turned When Having Trouble Falling

Asleep, SANOFI (last visited July 1, 2020), https://www.ambien.com/.
2

Joanne Kaufman, Think You’re Seeing More Drug Ads on TV? You Are, and Here’s Why, N.Y.

TIMES (Dec. 24, 2017), https://www.nytimes.com/2017/12/24/business/media/prescriptiondrugs-advertising-tv.html. This is most likely a result of the existing regulations addressing
broadcast, radio, and print mediums directly. Prescription Drug Advertisements, 21 C.F.R. §
202.1 (2019).
3

Nitasha Tiku, Facebook has a Prescription: More Pharmaceutical Ads, WASH. POST (Mar. 4,

2020), https://www.washingtonpost.com/technology/2020/03/03/facebook-pharma-ads/ (finding
companies are beginning to ramp up their social media advertising).
4

Direct-to-consumer (DTC) advertising is where a company advertises its product information to

the consumer instead of healthcare professionals. Direct-to-Consumer (DTC) Advertisements,
Drug Advertising: A Glossary of Terms, U.S. FOOD & DRUG ADMIN. (last visited July 20, 2020),
https://www.fda.gov/drugs/prescription-drug-advertising/drug-advertising-glossary-terms#dtc.
1

has performed health research online.5 Thirty-seven percent of internet users specifically looked
for information on prescription drugs.6 With these levels of consumer activism about their
health, it is unsurprising to see a proliferation of DTC advertising to users on the Internet, and
specifically placing these advertisements to social media.7
In 2018, the pharmaceutical industry spent $6.1 billion on advertising, with $5.1 billion
spent on television ads.8 In 2019, the healthcare and pharmaceutical industry spent $3.62 billion
on digital advertising.9 As indicated by these figures, advertising is of immense scale. With the
advent of social media platforms, pharmaceutical companies could reach new and existing
consumers through these new types of forums and media outlets. However, this medium has
remained in regulatory limbo since 2014—the last time the FDA issued a guidance document

5

Most Internet Users Start at a Search Engine When Looking for Health Information Online,

PEW RES. CTR. (Oct. 29, 2006), https://www.pewresearch.org/internet/2006/10/29/online-healthsearch-2006/ (finding eighty percent of American internet users searched for health information).
6

Id.

7

See Tiku, supra note 3 (commenting industry is now beginning to advertise more heavily on

social media).
8

Alison Kanski, Nielsen: Pfizer Tops List of Biggest Pharma Advertisers in 2018, MED., MKTG,

& MEDIA (Apr. 2, 2019), https://www.mmmonline.com/home/channel/nielsen-pfizer-tops-list-ofbiggest-pharma-advertisers-in-2018/.
9

Ross Benes, Digital Ad Spending by Industry 2019, EMARKETER (Aug. 1, 2019),

https://www.emarketer.com/content/digital-ad-spending-by-industry-2019.
2

pertaining by name to social media.10 Enforcement against companies advertising prescription
drugs using social media began with a warning letter issued in 2010 against Novartis
Pharmaceuticals for developing a shareable Facebook widget.11 This letter highlighted an
important theme for existing guidance and regulations— presentation of the risk information.12
“Social media” describes a burgeoning set of platforms where people can share ideas and
communicate with one another.13 User bases vary across platforms, with Facebook as a clear

10

U.S. FOOD & DRUG ADMIN., DRAFT GUIDANCE FOR INDUSTRY: INTERNET/SOCIAL MEDIA

PLATFORMS: CORRECTING THIRD-PARTY MISINFORMATION ABOUT PRESCRIPTION DRUGS AND
MEDICAL DEVICES (2014) [hereinafter THIRD-PARTY MISINFORMATION GUIDANCE]; U.S. FOOD
& DRUG ADMIN., DRAFT GUIDANCE FOR INDUSTRY: INTERNET/SOCIAL MEDIA PLATFORMS WITH
CHARACTER SPACE LIMITATIONS—PRESENTING RISK AND BENEFIT INFORMATION FOR
PRESCRIPTION DRUGS AND MEDICAL DEVICES (2014) [hereinafter CHARACTER LIMIT GUIDANCE].
11

Letter to Lisa Drucker, Novartis Pharm. Corp., from Karen R. Rulli, FDA, 2–3 (July 29,

2010),
http://wayback.archiveit.org/7993/20170112062707/http://www.fda.gov/downloads/Drugs/Guida
nceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeo
fViolationLetterstoPharmaceuticalCompanies/UCM221325.pdf (accessed May 23, 2020)
[hereinafter Tasinga Warning Letter] (the Tasinga widget omitted the risk information).
12

Id. at 2–4.

13

See Social Media, BLACK’S LAW DICTIONARY (11th ed. 2019); Social Media, MERRIAM

WEBSTER (last visited July 3, 2020). Scholars have characterized applications from networking
sites like Facebook to virtual game worlds like World of Warcraft are social media. Andreas M.
3

leader with nearly two-and-a-half billion users.14 Some other familiar platforms like YouTube
and Twitter have two billion and 386 million users, respectively.15 These high usage statistics
also have a tremendous variance in the age of the user.16 Each of these platforms has a unique
way of allowing users to interact and collaborate, and useful for businesses, targeted advertising
services, which this Comment refers collectively as “functionality.”17

Kaplan & Michael Haenlein, Users of the World, Unite! The Challenges and Opportunities of
Social Media, 53 BUS. HORIZONS 59, 62 (2010).
14

J. Clement, Most Popular Social Networks Worldwide as of April 2020, Ranked by Number of

Active Users, STATISTA (Apr. 24, 2020), https://www.statista.com/statistics/272014/globalsocial-networks-ranked-by-number-ofusers/ (also reporting other platforms, like TikTok and
Snapchat have ascertained 800 million users and 398 million users respectively).
15

Id.

16

Social Media Fact Sheet, PEW RES. CTR. (last visited Aug. 21, 2020),

https://www.pewresearch.org/internet/fact-sheet/social-media/ (finding that over fifty percent of
individuals aged eighteen to sixty-five years old have at least one social media account).
17

Facebook for Business, FACEBOOK (last visited Aug. 21, 2020),

https://www.facebook.com/business/ads/ad-targeting; Twitter Ads Targeting, TWITTER (last
visited Aug. 21, 2020), https://business.twitter.com/en/advertising/targeting.html. For the
purposes of this Comment, functionality also includes constraints in the ability to express and
manifest an idea. See, e.g., “Tweet,” Glossary, TWITTER, https://help.twitter.com/en/glossary
(last visited July 8, 2020) (where a tweet is limited to 280 characters and may contain photos and
video content); “Single Image or Video Ads,” Snapchat Ad Specs, SNAPCHAT,
4

This Comment will explore how to address social media as a new medium for advertising
in three parts. Part I discusses the creation and evolution of the Food, Drug, and Cosmetics Act’s
(FDCA’s) drug approval scheme and relevant statutory provisions for protecting the public
health. Part II discusses the guidance documents the FDA has issued on social media and
discusses the weaknesses of each one. It then includes a discussion of the critical First
Amendment case law in the realm of drugs, with a comprehensive analysis of how one of the
guidance documents would stand with the First Amendment jurisprudence if challenged.
Finally, Part III offers guidance to the FDA for how it should consider social media functionality
in its thinking. It then offers practical methods for how the FDA could update existing guidance
or issue new guidance and use its notice-and-comment rulemaking procedures to update existing
provisions when approaching social media functionality and DTC prescription drug advertising.
I.

THE DEVELOPMENT AND PROVISIONS OF THE FDCA
A. Development of the FDCA

Congress took one of its first major steps to enhance food and drug regulation in 1906,
when it created a criminal offense for individuals who were misbranding food and drugs.18 This

https://businesshelp.snapchat.com/en-US/article/top-snap-specs (last visited July 8, 2020) (where
ads may be single image or videos and last from three seconds to three minutes).
18

Pub. L. No. 59-384 (1906). See generally Jillian London, Tragedy, Transformation, and

Triumph: Comparing the Factors and Forces that Led to the Adoption of the 1860 Adulteration
Act in England and the 1906 Pure Food and Drug Act in the United States, 69 FOOD & DRUG
L.J. 315. 327–29, 336–41 (2014) (comparing the factors leading to England and the United States
5

legislation, however, did not include evaluation requirements for safety and efficacy; a change
that arrived over the next few decades.19 However, the legislation’s intent and purpose of
protecting the public health persisted as food and drug regulation evolved.20 In 1906, a “drug”
was “all medicines and preparations recognized in the United States Pharmacopoeia or National
Formulary . . . to be used for the cure, mitigation, or prevention of disease either by man or other
animals,” but was amended to include additional definitions of what a drug could be.21

drug regulatory regimes); infra Part I(B) (explaining misbranding). Present provisions on food
and drug misbranding can be found at FDCA §§ 403, 502, 21 U.S.C §§ 343, 352 (2018).
19

Pub. L. No. 59-384.

20

See H.R. REP. NO. 2139, at 1–2 (1938) (commenting that the Food, Drug, and Cosmetic Act’s

(FDCA’s) purpose “amplifies and strengthens the provisions designed to safeguard the public
health and prevent deception . . . .”).
21

Compare Pub. L. No. 59-384, § 6 (defining drug as “all medicines and preparations”

recognized by the National Formulary (NF) to be used in the treatment of disease), with 21
U.S.C. § 321(g)(1)–(2) (2018) (which includes, in part, medicines recognized in the NF, but adds
the definition of a “counterfeit drug”), and 21 U.S.C. § 321(p) (2018) (where the drug definition
describes a “new drug”). See also Lewis A. Grossman, Food, Drugs, and Droods: A Historical
Consideration of Definitions and Categories in American Food and Drug Law, 93 CORNELL L.
REV. 1091, 1104–8, 1112–18 (2008) (exploring the differences between the definitions of “drug”
in the 1906 Pure Food and Drug Act and the FDCA).
6

Congress members began drafting a replacement law beginning as early as 1933.22
However, passage would come after a paradigmatic moment in 1937 when an estimated ninety
people died as a result of the S. E. Massengill Company distributing more than 240 gallons of a
drug containing deadly chemical.23 The replacement of the 1906 Act occurred in 1938 with the
introduction of the FDCA on January 6, 1937.24 Senator Royal Copeland, urging the passage of
a new law, emphasized the purpose of a new food and drug bill was to protect society from such
tragedies.25 This major update included the beginning of what would evolve into the robust
premarket review of drugs that exists today.26 The existing model for premarket review came
after the Thalidomide crisis in Europe.27 Following the crisis, Representative Oren Harris of
Arkansas proposed amendments to the FDCA in 1962.28 These amendments created the

22

David F. Cavers, The Food, Drug, and Cosmetic Act of 1938: Its Legislative History and Its

Substantive Provisions, 6 L. & CONTEMP. PROBS. 2, 6 (1939).
23

PETER BARTON HUTT ET AL., FOOD AND DRUG LAW: CASES AND MATERIALS 642 (4th ed.

2013); Cavers, supra note 22, at 20.
24

Federal Food, Drug, and Cosmetic Act, S. 5, 75th Cong. (1937).

25

83 CONG. REC. 6264 (1938).

26

Federal Food, Drug, and Cosmetic Act, S. 5, 75th Cong., § 505 (1938). See also Hutt, supra

note 23, at 642 (noting that the process at this time functioned as a “notification” system).
27

Hutt, supra note 23, at 642. See generally Anita Bernstein, Formed by Thalidomide: Mass

Torts as a False Cure for Toxic Exposure, 97 COLUM. L. REV. 2153 (1997).
28

H.R. REP. NO. 87-2464, at 1–2 (1962). Some additional objectives included factory

inspections and new procedures to follow for testing new drugs. Id. at 1–2.
7

comprehensive drug review process that exists today with the “[r]equirement that new drugs be
shown to be effective as well as safe.”29 For prescription drugs, these amendments also
conferred important authority to the FDA with control over the advertising of such products.30
This history is here to highlight an oft-cited objective for the FDA to serve as protector of
the public health.31 Social media adds another dimension of complexity to the FDA’s pursuit of
this objective.32 On the one hand, consumer deception is at the forefront.33 In a similar vein,
DTC advertising on social media likely revives similar challenges the FDA faced when it first
began regulating DTC ads.34 The other side of the equation involves the possibility of a direct

29

Id. at 1. See also FDCA § 505(b)(1)(A), 21 U.S.C. § 355(b)(1)(A) (2018) (requiring a

manufacturer to prove whether the drug is safe and effective for intended use).
30

Hutt, supra note 23, at 907.

31

See, e.g., United States v. Caronia, 703 F.3d 149, 166 (2d Cir. 2012); Amarin Pharma, Inc. v.

U.S. Food & Drug Admin., 119 F. Supp. 3d 196, 217 (S.D.N.Y. 2015); Wash. Legal Found. v.
Friedman, 13 F. Supp. 2d 51, 57 (D.C. Cir. 1998).
32

Social media presents variable functionality industry could use to interact and engage

consumers. Tiku, supra note 3 (finding companies are beginning to promote on social media).
33

See THIRD-PARTY MISINFORMATION GUIDANCE, supra note 10, at 3 (commenting that third-

party content may be hazardous to public health); CHARACTER LIMIT GUIDANCE, supra note 10,
at 5 (claiming that “truthful, accurate, non-misleading, and balanced product information” will
best serve the public health).
34

See Jacqueline West, National Marketing Gone Unintentionally Global: Direct-to-Consumer

Advertising of Pharmaceutical Products and the Internet, 11 J. INT’L BUS. & L. 405, 412 (2012)
8

challenge to the very core of the drug approval process: an avenue that could lead to off-label
promotion.35 Clear from the history, however, are that drugs come under close scrutiny and with
this scrutiny comes an agency charged with monitoring the commercial posture taken by
manufacturers on these products.36
B. Labeling, Misbranding, and Advertising a Prescription Drug
In the current model of the FDCA, several provisions directly address the rules regarding
the labeling and advertising of a drug.37 Further, additional rules are outlined in the CFR to help
expound on the expectations set by the FDA.38 The FDCA defines a label as “a display of
written, printed, or graphic matter upon the immediate container of any article . . . .”39 It then

(summarizing how the “brief summary” requirement was a challenge for the FDA for broadcast
advertising).
35

See infra Parts I(B), II(C) (defining off-label promotion and exploring the challenges courts

have placed in the FDA’s path).
36

See infra Part I(B) (covering the statutory and regulatory tools the FDA has to review the

potential misbranding of a drug).
37

See, e.g., FDCA §502(f), (n), 21 U.S.C. § 352(f), (n) (2018). Inversely, the labeling

requirements might be easy to understand by seeing what the labeling should avoid for fear of
being deemed misbranded (a topic that will be discussed shortly). See, e.g., § 352(a)(1) (“a drug
. . . shall be deemed to be misbranded if its labeling is false or misleading in any particular”).
38

21 C.F.R. §§ 201.1, 201.100, 202.1 (2019).

39

FDCA § 201(k), 21 U.S.C. § 321(k).
9

classifies “labeling” to include “all labels and other written, printed, or graphic matter (1) upon
any article or any of its containers or wrappers, or (2) accompanying such article.”40
For enforcement and compliance with the FDCA, misbranding is a common cause of
action.41 The FDCA grants the FDA many tools to make a case about an article being
misbranded.42 One tool is section 201(n), which allows the FDA to review “not only
representations made or suggested . . . but also the extent to which the labeling or advertising
fails to reveal facts material . . . under the conditions of use . . . .”43 In Kordel v. United States,
the Court gave the language of section 201(m) a very liberal construction, holding “it is the
textual relationship that counts.”44 These two provisions plus Kordel are valuable for the FDA
when determining a misbranding violation.

40

FDCA § 201(m), 21 U.S.C. § 321(m).

41

See, e.g., United States v. Evers, 643 F.2d 1043, 1044 (5th Cir. 1981) (suit against a physician

for misbranding a drug when giving information about its use to his patients); Alberty Food
Products v. United States, 194 F.2d 462, 463 (9th Cir. 1952) (literature distributed to prospective
consumers failed to demonstrate, among other things, diseases the drug was intended to cure).
42

FDCA §§ 201(n), 301(a)–(b), 502(a)(1), (n), 21 U.S.C §§ 321(n), 331(a)–(b), 352(a)(1), (n).

43

FDCA § 201(n), 21 U.S.C. § 321(n).

44

335 U.S. 345, 350 (1948) (finding articles and accompanying literature can “supplement” each

other and no physical attachment to the article is necessary).
10

Section 502 of the FDCA is devoted specifically to drugs.45 Under this section,
misbranding can occur when the “labeling is false or misleading in any particular.”46 Another
form of misbranding occurs when a label fails to reveal material facts, for example, “adequate
directions for use.”47 These adequate directions for use are defined as “directions for which the
layman can use a drug safely and for the purposes for which it is intended.”48 These directions
may be found inadequate because “of omission . . . or incorrect specification of (a) statements of
all conditions, purposes, or uses for which such drug is intended . . . (b) quantity of dose . . . (c)
frequency of administration . . . .”49
A drug that is not approved for a specific use, under which there is no general recognition
by scientists qualified to evaluate safety and efficacy of the drug for that use, is considered a
“new drug.”50 Promoting a drug as such violates section 505(a) for “introduction into interstate
commerce any new drug, unless approval of an application . . . is effective with respect to such

45

FDCA § 502, 21 U.S.C. § 352.

46

§ 352(a)(1).

47

FDCA §§ 201(n), 502(f)(1), 21 U.S.C. §§ 321(n), 352(f)(1).

48

Labeling, 21 C.F.R. § 201.5 (2019). For example, a failure to include how to properly prepare

the drug for use could be found inadequate. § 201.5(g).
49

§ 201.5(a)–(c). The regulation also provides that other factors, like the method of

administration and information about preparation, are some other possibilities. § 201.5(f), (g).
50

FDCA § 201(p)(1), 21 U.S.C. § 321(p)(1).
11

drug.”51 This in conjunction with FDCA section 301(a), creates the prohibition against what is
known as “off-label promotion” because promotion must be consistent with the FDA approved
labeling.52 These prohibitions are important for social media considerations because if a firm is
going to promote its product, it must do so in accord with the FDA approval of its product.53
Failure to do so will likely result in a misbranding action taken by the FDA against the offending
party.54
The FDA recognizes several types of advertisements manufacturers may employ to
promote their products.55 The main types of advertisements are “Product Claim” advertisements,
“Reminder” advertisements, and “Help-seeking” advertisements.56 A “Product Claim”
advertisement is one that names the drug and discusses the benefits and risks.57 In a print
medium, these advertisements must include a “brief summary,” which includes all the known

51

FDCA § 505(a), 21 U.S.C. § 355(a). The basic elements of what a new drug application looks

like can be found under subsection (b)(1) of the same statute.
52

FDCA § 301(a), 21 U.S.C. § 331(a).

53

Id.

54

See, e.g., United States v. Caronia, 703 F.3d 149, 157 (2d Cir. 2012) (one of the counts against

Mr. Caronia was a conspiracy to introduce a drug into interstate commerce that was misbranded).
55

Basics of Drug Ads, U.S. FOOD & DRUG ADMIN., https://www.fda.gov/drugs/prescription-

drug-advertising/basics-drug-ads (last visited July 5, 2020).
56

Id.

57

Id. This will be the most pivotal type of advertisement discussed by this Comment in Part III.
12

risks posed by the drug.58 If done through a broadcast medium, the advertisement must include a
“major statement,” which is a communication of the most important risks and how viewers may
locate more risk information.59 A “Reminder” advertisement does not disclose risk information,
but simply provides the audience the name of the drug without including indications the drug is
approved for.60 “Help-seeking” advertisements are interesting because when created “properly,”
they are not supposed to be drug advertisements.61 These types of ads fall under the Federal
Trade Commission’s (FTC’s) purview.62 Lastly, FDA states that “Other Product Claim
Promotional Material” is “promotional labeling” and if these materials mention a drug’s benefits,
they must also include the prescribing information.63

58

FDCA § 502(n)(3), 21 U.S.C § 352(n)(3); Prescription Drug Advertisements, 21 C.F.R. §

202.1(e)(1) (2019); Basics of Drug Ads, supra note 55. The “brief summary” forbids advertisers
from suggesting the use of the drug for an unapproved indication. § 202.1(e)(iii)(4)(i)(a).
59

§ 202.1(e)(1); Basics of Drug Ads, supra note 55. The CFR provides that the major statement

applies to broadcasts through radio, television, or telephone. § 202.1(e)(1).
60

§ 202.1(e)(2)(i); Basics of Drug Ads, supra note 55. Prescription drugs that contain boxed

warnings in their labeling are prohibited from using these advertisements. § 202.1(e)(2)(i).
61

Basics of Drug Ads, supra note 55.

62

Id. However, if they mention or suggest a specific drug, the FDA will retain purview. Id.

63

Id. The FDA defines “promotional labeling” as items distributed to consumers, like brochures

and cups, among other things. “Promotional Labeling,” Drug Advertising: A Glossary of Terms,
U.S. FOOD & DRUG ADMIN., https://www.fda.gov/drugs/prescription-drug-advertising/drugadvertising-glossary-terms#P (last visited July 7, 2020).
13

These types of advertisements are important because each type comes with unique
requirements.64 When considering these for social media functions, some may be better suited
than others for certain mediums.65 If the advertisement form is a “Help-Seeking” advertisement,
then the jurisdiction itself shifts from the FDA to the FTC, which can be a limitation on the
FDA’s capacity to review an advertisement.66 An important challenge to consider with “Product
Claim” advertisements are how social media functions can be used to navigate the “brief
summary” requirement.67
II.

SOCIAL MEDIA GUIDANCE AND THE FIRST AMENDMENT
A. FDA’s Social Media Guidance

In furtherance of this statutory evolution as an arbiter of the public health, the
Administrative Procedure Act (APA) creates a process the FDA must adhere to when
promulgating new rules that carry the force of law.68 However, there is also an exemption for it
to issue “interpretative rules, general statements of policy, or rules of agency organization,
procedure, or practice.”69 It is precisely this exemption in the process that allows the FDA to

64

See Basics of Drug Ads, supra note 55.

65

The FDA acknowledges this for reminder advertisements because those ads do not require the

same amount of disclosure. CHARACTER LIMIT GUIDANCE, supra note 10, at 4.
66

Basics of Drug Ads, supra note 55.

67

FDCA § 502(n)(3), 21 U.S.C. § 352(n)(3) (2018).

68

Administrative Procedure Act (APA), 5 U.S.C. § 553 (2018).

69

APA, § 553(b)(A).
14

issue a guidance document, which consists of its thinking on a particular subject and how it
believes case law and statute apply.70
Although the FDA presently maintains two guidance documents with the term “social
media” in the title, the agency has otherwise minimally addressed the subject.71 The two
documents focus on two main points: (1) how the FDA believes firms should approach
correcting misinformation disseminated by third parties and (2) how firms should approach using
social media sites and advertising mediums with character constraints.72 Both of these
documents draw their strength from similar roots—the labeling and misbranding provisions
granted by the FDCA.73 Discussion of these documents in depth will demonstrate that the FDA
is thematically concerned with the public health and making sure the public has the best
information to make informed decisions related to their health.74 However, these guidance

70

See, e.g., THIRD-PARTY MISINFORMATION GUIDANCE, supra note 10, at 1; CHARACTER LIMIT

GUIDANCE, supra note 10, at 1.
71

THIRD-PARTY MISINFORMATION GUIDANCE, supra note 10; CHARACTER LIMIT GUIDANCE,

supra note 10.
72

THIRD-PARTY MISINFORMATION GUIDANCE, supra note 10; CHARACTER LIMIT GUIDANCE,

supra note 10.
73

See THIRD-PARTY MISINFORMATION GUIDANCE, supra note 10, at 2–3; CHARACTER LIMIT

GUIDANCE, supra note 10, at 2–3; see also supra Part I(B) (discussing the relevant provisions).
74

THIRD-PARTY MISINFORMATION GUIDANCE, supra note 10, at 3; CHARACTER LIMIT

GUIDANCE, supra note 10, at 5.
15

documents fall short of addressing the First Amendment case law and commercial speech
protections in issuing these guidance documents, which will be important for future guidance.
1. Third-Party Misinformation Guidance
The third-party misinformation guidance suggests how firms “should respond, if they
choose . . . to misinformation related to a firm’s own FDA-approved or -cleared products . . .
when that information is created or disseminated by independent third parties.”75 The FDA
recognizes that firms are “generally not responsible” for third-party content about their product,
but could be if it “solicit[ed] or influence[d]” the content.76 Section four of the guidance
indicates how firms should communicate a correction request.77 Among the suggestions, the
FDA highlights firms be “non-promotional in nature” and “consistent with the FDA-required
labeling for the product.”78 The FDA also suggests firms include the approved labeling in their
communications.79 If the product is a prescription drug, it should be “supported by sufficient
evidence, including substantial evidence.”80

75

THIRD-PARTY MISINFORMATION GUIDANCE, supra note 10, at 1 (emphasis added).

76

Id. at 5.

77

Id. at 5–6.

78

Id.

79

Id. at 6.

80

Id. “Substantial evidence” means “adequate and well-controlled investigations . . . to evaluate

the effectiveness of the drug” FDCA § 505(d), 21 U.S.C. § 355(d) (2018).
16

The FDA recognizes the challenge that exists in trying to correct an entire forum due to
the vast amount of information.81 The FDA does not expect a firm to seek to correct every piece
of information that exists on a particular site.82 If a firm elects to correct some of the
misinformation, it should “clearly identify the misinformation it is correcting, define the portion
of the forum . . . and should correct all the misinformation that appears in that clearly defined
portion.”83 However, a firm may not correct only some of the misinformation in a defined
section; it must address it all.84 In addressing the defined section, the FDA offers several
suggestions.85 Some of the methods include directly correcting the misinformation on the forum,
providing corrective information to the author, requesting removal of the post, or contacting a
site administrator.86 If the posts cannot be removed, the FDA requests firms keep records about
its efforts addressing the misinformation.87

81

THIRD-PARTY MISINFORMATION GUIDANCE, supra note 10, at 6.

82

Id. at 7.

83

Id.

84

For example, if the firm chooses to correct information that negatively publicizes its product

and ignores a clear overstatement of the product’s benefits in the same defined section, the firm
has failed to adhere to the guidance. Id.
85

Id. at 7–8.

86

Id.

87

Id. at 9.
17

With all guidance documents, they are merely suggestions with no force of law and offer,
at best as the name suggests, guidance on a topic.88 Dodging enforcement action, however, is
valuable to a firm, so these documents do come with some bite.89 One of the challenging
elements of this guidance is that, if a firm chooses to engage in correcting misinformation, it
should do so in a manner that narrowly limits itself to the specific element that is creating the
misinformation.90 This creates a content-based burden, which could prove problematic if the
FDA is going to suggest a limit to a firm’s ability to respond to misinformation.91 Additionally,
it offers that a firm not be “promotional in nature or tone,” which suggests a speaker-based
burden, which is subject to a rigorous review under existing case law.92
2. Character Limit Guidance
The character limit guidance applies to a firm presenting the benefit information of its
drug and stating it should also incorporate the risk information of it in “electronic/digital

88

FDCA § 701(h)(1)(A), 21 U.S.C. § 371(h)(1)(A) (2018); see also Hutt, supra note 23, at 30

(highlighting how the FDA has increasingly used this tool).
89

See generally Lars Noah, Governance by the Backdoor: Administrative Law(lessness?) at the

FDA, 93 NEB. L. REV. 89, 122–24 (2014) (surveying the value of compliance with guidance).
90

See, e.g., THIRD-PARTY MISINFORMATION GUIDANCE, supra note 10, at 6 (where example 5

discusses that information should be limited to the indication in question); see also infra Part
II(B)(1) (discussing burdens on speech and applicable case law).
91

See Sorrell v. IMS Health, Inc., 564 U.S. 552, 581 (2011) (“content-based burdens on

protected expression are sufficient to justify an application of heightened scrutiny”).
92

Sorrell, 564 U.S. at 572; THIRD-PARTY MISINFORMATION GUIDANCE, supra note 10, at 5.
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platforms that are associated with character space limitations—specifically on the Internet and
through social media . . . .”93 The document provides two mediums for examples, namely
Twitter’s “tweet” and Google’s sponsored link service.94 It is not intended to apply to
promotions on “product websites” or webpages that appear on social media (like product pages
on Facebook, Twitter, or YouTube) because the FDA believes the same constraints do not
exist.95
In a character-limited platform, if a firm presents the benefit information, it should also
discuss the risks.96 In presenting these two elements, the presentation should be of comparable
“content and prominence.”97 Additionally, the FDA advises firms to provide a link to a place
where a “more complete discussion” of the risk information.98 The guidance further highlights
when crafting an advertisement or promotional statement, the “benefit information should be
accurate and non-misleading and reveal material facts within . . . .”99

93

CHARACTER LIMIT GUIDANCE, supra note 10, at 1.

94

Id. at 1–2.

95

Id. at 2.

96

CHARACTER LIMIT GUIDANCE, supra note 10, at 5.

97

Id. at 4; see also Prescription Drug Advertisements, 21 C.F.R. § 202.1(e)(5)(ii) (2019)

(requiring the information be presented as a fair balance).
98

CHARACTER LIMIT GUIDANCE, supra note 10, at 5.

99

Material facts are about the use could be limitations to an indication or relevant population for

treatment. Id. at 6.
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The FDA offers two factors to evaluate the comparability in presentation of the risk
versus the benefit: (1) whether the risk qualifies a representation about the product and (2)
whether the risk has the same prominence and readability as the benefit information.100 At a
minimum, the FDA suggests “the most serious risks associated with the product” be
communicated.101 For prescription drugs, “the most serious risks” are those in a “boxed
warning,” either fatal or life-threatening, or all contraindications found within the approved
labeling.102 When providing a mechanism to communicate information beyond the tweet, the
FDA suggests a “direct” hyperlink to a page that is “devoted exclusively to comprehensive risk
information . . . .”103
To help emphasize the comparability of the risk and benefit disclosures, the FDA
suggests firms use the same emphasis that highlights the benefit information on the risk

100

Id. at 8.

101

Id. at 9.

102

Id. A “boxed warning” is a warning that a drug “may lead to death or serious injury . . . .”

Labeling, 21 C.F.R. § 201.57(c)(1) (2019). A “contraindication” is a condition when the drug
“should not be used . . . .” “Contraindication,” MEDLINEPLUS,
https://medlineplus.gov/ency/article/002314.htm (last visited July 21, 2020).
103

Some examples of direct information offered are “landing pages” with information

exclusively focused on risks or a PDF outlining the information. CHARACTER LIMIT GUIDANCE,
supra note 10, at 10. Firms may use URL condensing services to help fit the information.
CHARACTER LIMIT GUIDANCE, supra note 10, at 10.
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information as well.104 If the medium offers the ability to accentuate or reformat specific parts of
the message, the FDA advises firms to use that formatting to highlight significant risk
information.105 In formulation of the messages, the FDA permits the use of commonly utilized
acronyms and symbols to assist with shrinking the size of the message to permit the balance of
benefits and risks.106
While these guidance documents begin tackling social media to ensure drugs are
characterized in a consistent and balanced manner, they leave room for improvement. An
important shortcoming of the character limit guidance is its failure to explore the First
Amendment jurisprudence in suggesting certain manufacturers avoid using those characterlimited platforms.107 This is further exacerbated since the suggestions made by the FDA create a
speaker-based burden that suggests manufacturers try to comply with rigid requirements in a

104

Id. at 10–11.

105

For prescription drug messages, one example is reformatting a boxed warning for more

prominence. Id. at 11.
106

Id. at 14.

107

Industry highlights this case in its comments. See Washington Legal Foundation, Comment

Letter Concerning Draft Guidance for Industry on Internet/Social Media Platforms with Space
Character Limitations, 4–6 (Sept. 16, 2014), https://www.regulations.gov/document?D=FDA2014-D-0397-0019 [hereinafter WLF Letter]; Medical Information Working Group, Draft
Guidance for Industry: Internet/Social Media Platforms with Character Space Limitations
(Docket No. FDA-2014-D-0397), 4–5 (Sept. 16, 2014) [hereinafter MIWG Letter].
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narrowly defined space.108 While leveraging how the failure to reveal material facts could lead
to the misbranding of a drug, the guidance does not clearly demonstrate a nexus as to how a
consumer is more likely to be misled by an advertisement on this platform.109 A larger takeaway
is that both guidance documents do not address the differing functionality that social media
provides.110 While the documents were issued in the advent of social media, silence on the

108

See Sorrell v. IMS Health, Inc., 564 U.S. 552, 571 (2011) (finding content- and- speaker

based burdens on expression warrant heightened judicial scrutiny and subsequently applying
Central Hudson to that effect); Pharmaceutical Research and Manufacturers of America, Draft
Guidance for Industry on Internet/Social Media Platforms with Character Space Limitations
(Docket No. FDA-2014-D0397), 8, n. 29 (Sept. 16, 2014) [hereinafter PhRMA Letter]
(commenting that risk disclosures creates a speaker-based burden, subject to heightened scrutiny
under Sorrell).
109

The guidance relies heavily on section 201(n), but a reviewing court or industry challenge

would likely assert mere probability of deception is insufficient. See Cent. Hudson Gas & Elec.
Corp. v. Pub. Serv. Comm’n of N.Y., 447 U.S. 557, 563 (1980) (“government may ban forms for
communication more likely to deceive the public . . . .”) (emphasis added).
110

See Cook Group, Inc., Docket No. FDA-2014-D-0447 Draft Guidance for Industry:

Internet/Social Media Platforms: Correcting Independent Third-Party Misinformation, 3 (Sept.
16, 2014) [hereinafter Cook Letter] (commenting that the FDA should more “broadly reflect” the
differing social media platforms that exist); Advanced Medical Technology Association, Docket
No. FDA-2014-D-0397; Draft Guidance for Industry on Internet/Social Media Platforms with
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matter since then provides room for amending or issuing new guidance to address the evolving
platforms and address existing industry concerns.111
B. The First Amendment
1. Commercial Speech Doctrine
Commercial speech protections were not readily recognized until Virginia State Board of
Pharmacy v. Virginia Citizens Consumer Council, Inc.112 This case originated from a state law
that prohibited pharmacists from publishing, advertising, or promoting information about the
pricing of a prescription drug.113 Justice Blackmun found “society . . . may have a strong interest
in the free flow of commercial information.”114 He observed that “the poor, the sick, and
particularly the aged” are most afflicted by the hiding of prescription drug prices.115
In recognizing the legal protection of commercial speech, Justice Blackmun offered that
“we of course do not hold that it can never be regulated in any way.”116 He then listed typically

Character Space Limitations, 2 (Sept. 16, 2014) [hereinafter AdvaMed Letter] (noting the FDA
should take an approach that better reflects the “unique” attributes of social media).
111

See infra Part III(B) (discussing how the FDA could issue new guidance to address this).

112

425 U.S. 748, 770 (1976). “Commercial Speech” is defined as “[c]ommunication (such as

advertising and marketing) that involves only the commercial interests of the speaker and the
audience . . . .” Speech, BLACK’S LAW DICTIONARY (11th ed. 2019).
113

425 U.S. at 749–50 (quoting VA. CODE ANN. § 54-524.35 (1974)).

114

Id. at 764.

115

Id. at 763.

116

Id. at 770.
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upheld restrictions, namely: those that are not content restrictive, serve an important government
interest, or leave open ample alternative channels for communication.117 The lone dissenter,
Justice Rehnquist, explained his disagreement with the majority, believing the First Amendment
services “public decisionmaking as to political, social, and other public issues” and not the
“purchase one or another kind of shampoo.”118
This case has several important considerations for applicability to social media functions.
First, Justice Blackmun recognizes that commercial speech is not immune to speech restrictions,
which provides supportive language for the FDA to continue to regulate advertising and do so
for information posted by a manufacturer on social media or equivocated through a function of
social media.119 Justice Blackmun was keen to note that “society . . . may have a strong interest
in the free flow of commercial information” and that, while advertising might be viewed as
“excessive,” dissemination of this information is useful for consumer decisions.120 Social media

117

Id. at 771.

118

Id. at 787 (Rehnquist, J., dissenting). Justice Rehnquist feared this ruling would go beyond

simple display of price information, instead leading to “active promotion of prescription drugs,
liquor, cigarettes, and other products . . . thought desirable to discourage.” Id. at 781 (Rehnquist,
J., dissenting). See, e.g., Lorillard Tobacco Co. v. Reilly, 533 U.S. 525, 526 (2001) (striking
down a law prohibiting outdoor and point-of-sale promotion of smokeless tobacco products and
cigars); 44 Liquormart, Inc. v. Rhode Island, 517 U.S. 484, 516 (1996) (striking down a law
prohibiting the promotion of liquor prices).
119

Va. St. Bd. of Pharm., 425 U.S. at 770.

120

Id. at 764–65.
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can easily become a vehicle for these advertisements, which provides an important rationale for
both industry and the FDA to come together and identify meaningful methods of regulation.121
The signature test for commercial speech analysis came with Central Hudson Gas and
Electric Corp. v. Public Service Commission of New York.122 The Court created a four-part legal
inquiry into commercial speech restrictions.123 To evaluate the permissibility of a commercial
speech burden, a court must first determine whether the speech is false or misleading.124 If the
speech is found truthful and not misleading or concerns lawful activity, the court must find the
government asserted a substantial interest.125 To sustain the speech restriction, the burden on
speech must directly advance that interest and be no more extensive than necessary to achieve

121

See infra Part III (explaining how the FDA can provide meaningful solutions and address

existing industry concerns). Justice Blackmun also highlighted the “the poor, the sick, and
elderly” are often disproportionately affected by suppression of price information. Va. St. Bd. of
Pharm., 425 U.S. at 764. With digital platforms becoming a cheaper alternative, there could be
incentive for firms to reduce costs. See Brent Gleeson, “TV Advertising vs. Digital Marketing,”
FORBES (Nov. 20, 2012, 1:39 PM), https://www.forbes.com/sites/brentgleeson/2012/11/20/tvadvertising-vs-digital-marketing/#2ee1129037f8 (stating some advantages to digital advertising
are that it is cheaper and has better capacity to target specific consumer demographics).
122

447 U.S. 557 (1980).

123

Id. at 564, 572.

124

Id. at 564.

125

Id.
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that interest.126 In practice, the protection will not apply if the speech in question is false or
misleading.127 If the speech concerns lawful activity, is not misleading, and the government
asserts a substantial interest, then the court must review whether the asserted interest is directly
advanced by the regulation and whether it is more extensive than necessary.128
Central Hudson is the oft cited case when a commercial speech restriction is at issue.129
Addressing this case in guidance is imperative because it is a consistent topic industry mentions
when there are limitations and requirements present in proposed guidance.130 Central Hudson

126

Id.

127

See Id. at 566 (identifying speech that is unlawful or misleading is not protected). Recall a

drug is misbranded if “its labeling is false or misleading in any particular.” FDCA § 502(a)(1),
21 U.S.C. § 352(a)(1) (2018).
128

Central Hudson, 447 U.S. at 566. See, e.g., United States v. Caronia, 703 F.3d 149, 165–68

(2d Cir. 2012) (applying Central Hudson’s test in this manner).
129

See e.g., Thompson v. W. Sts. Med. Ctr., 535 U.S. 357 (2002) (challenging a provision of the

Food and Drug Administration Act of 1997 that exempts compounded drug manufacturers from
advertising); Lorillard Tobacco Co. v. Reilly, 533 U.S. 525 (2001) (challenging a statute
prohibiting the advertising of tobacco and smokeless tobacco products); 44 Liquormart, Inc. v.
Rhode Island, 517 U.S. 484 (1996) (challenging a state law prohibiting the advertising of alcohol
prices); Rubin v. Coors Brewing Co., 514 U.S. 476 (1995) (challenging the Federal Alcohol
Administration Act’s prohibition on beer labels displaying alcohol content).
130

See WLF Letter, supra note 107, at 4–6 (discussing that the First Amendment jurisprudence

grants constitutional protections to manufacturers); MIWG Letter, supra note 107, at 4.
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can help aide the FDA because if the speech in question does not concern lawful activity or is
misleading, it gives the FDA an opportunity to challenge the offending speech before needing to
defend its limitations on speech.131 Additionally, the FDA can use guidance to offer alternative
“channels” of communication on social media to show its restriction is not “more extensive than
necessary.”132 Performing these actions would demonstrate that the FDA is crafting policy in a
manner that shows it is trying to be as minimally restrictive as possible, a central element in
reviewing commercial speech inquiries.133
In the same vein of commercial speech, Sorrell v. IMS Health, Inc.134 articulated
“heightened scrutiny” analysis applies when there are content- and speaker-based burdens on
protected expression.135 This analysis is triggered by a “regulation of speech because of
disagreement with the message it conveys.”136 To survive the inquiry, the state must

131

Central Hudson, 447 U.S. at 566. If the FDA can successfully prove the speech is unlawful

or misleading, then the manufacturer that promoted its product in that manner will not be
afforded First Amendment protection. Id.
132

Id.; Va. St. Bd. of Pharm. v. Va. Citizens Consumer Council, Inc., 425 U.S. 748, 771 (1976).

By doing this, the FDA can address First Amendment jurisprudence, which neither existing draft
guidance does.
133

See Central Hudson, 446 U.S. at 566 (where a court will review if the government’s

restriction is more extensive than necessary).
134

546 U.S. 552 (2011).

135

Id. at 571 (2011).

136

Id. at 566 (quoting Ward v. Rock Against Racism, 491 U.S. 781, 791 (1989)).
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demonstrate “the statute directly advances a substantial government interest and that the measure
is drawn to achieve that interest.”137 In Sorrell, the Court struck down a Vermont law that failed
to meet this standard.138 While a small victory, the Court agreed that the public policy objectives
of promoting public health and lowering the costs of medical services were “proper.”139
This case has become foundational for its line “[s]peech in aid of pharmaceutical
marketing, however, is a form of expression protected by . . . the First Amendment.”140 This line
is now used against the FDA in both public comments on guidance as well as case law.141
Neither existing guidance targeting social media makes mention of this principle, which is
opportunity for improvement if the FDA decides to update these documents.142 Additionally, if
the FDA creates new guidance or rules surrounding social media usage, Sorrell is important to
address because its language appears inextricably linked to prescription drugs and

137

This “ensure[s]” the burden is proportional to the government’s interest(s). Id. at 572. See

also Central Hudson, 477 U.S. at 566 (listing the four-part intermediate scrutiny analysis).
138

Sorrell. 564 U.S. at 557.

139

Id. at 576.

140

Id. at 557.

141

See MIWG Letter, supra note 107, at 4 (commenting that the Character-Limit Guidance

creates a prohibition on some firm’s trying to use character limited platforms in violation of
Sorrell); infra Part II(C) (the cases discussing off-label promotion).
142

Doing so could quell the concern of the FDA’s lack of position on how these documents

comply with existing case law. See, e.g., MIWG Letter, supra note 107, at 4 (discussing the
constitutional issues).
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representations made about them.143 If the FDA chooses to pursue more formal rulemaking
related to prescription drug marketing on digital platforms broadly, this case certainly needs to
be addressed.144
2. Character Limit Guidance First Amendment Analysis
It is useful to run the FDA’s current thinking through existing legal frameworks to
evaluate whether it would stand under current precedent. While the FDA notes what a firm
“should” do, an enforcement action might be sufficient to trigger a First Amendment inquiry.145
The predominant standards to consider here are Sorrell and the Central Hudson, four-step
inquiry about commercial speech restrictions.146 The provision under review here is the FDA’s
suggestion that firms who cannot meet the “fair balance” requirement “reconsider” using a
platform with a character limit.147 A content-based burden on speech is created by enforcing

143

See Sorrell v. IMS Health, Inc., 564 U.S. 552, 557 (2011) (“[s]peech in aid of pharmaceutical

marketing . . . is a form of expression protected by the . . . First Amendment.”).
144

If there is a regulation of speech based on content, “heightened scrutiny” is going to apply.

Sorrell, 564 U.S. at 566; see infra Part III(B) (discussing how this could be done).
145

See, e.g., Amarin Pharma, Inc. v. FDA, 119 F. Supp. 3d 196, 222 (S.D.N.Y. 2015) (where a

warning letter sufficiently allowed Amarin to seek relief).
146

See supra Part II(B)(1) (discussing the commercial speech doctrine).

147

CHARACTER LIMIT GUIDANCE, supra note 10, at 5. Additionally, this analysis is done as if the

firm wants to use a “Product Claim” advertisement because the guidance was not intended to be
used on “Reminder” advertisements. CHARACTER LIMIT GUIDANCE, supra note 10, at 4, n. 10.
The “fair balance” requirement states that a firm must present information of comparable detail
29

that, in a character limited space, if a firm discusses the benefits it must also discuss the risks.148
If a firm cannot meet such requirement, then it should avoid using the platform.149 The criteria
used by a reviewing court will require the government to maintain a “substantial government
interest” and that “the measure is drawn to achieve that interest” in addition to the other Central
Hudson factors.150
On the Central Hudson question of whether the speech is false or misleading, the FDA’s
argument will be that tweets or other character limited posts are misleading because they do not
adequately disclose sufficient risk information against the benefits.151 Industry will rebuke the
FDA’s argument as impermissible because the FDA cannot restrict speech based on the notion
that the speech is not more likely to deceive the public than not.152 Industry might invoke the

between the side effects and contraindications and the effectiveness and safety. Prescription
Drug Advertisements, 21 C.F.R. § 202.1(e)(5)(ii) (2019).
148

Sorrell, 564 U.S. at 565; § 202.1(e)(5)(ii).

149

CHARACTER LIMIT GUIDANCE, supra note 10, at 5.

150

Sorrell, 564 U.S. at 572 (stating how the government must justify its content-based burden

and applying Central Hudson to evaluate that justification); see also Cent. Hudson Gas & Elec.
Corp. v. Pub. Serv. Comm’n of N.Y., 447 U.S. 557, 566 (1980) (laying out the four-part
commercial speech inquiry).
151

FDCA § 201(n), 21 U.S.C. § 321(n) (2018) (omitting risk information is a failure to reveal a

material fact); Central Hudson, 447 U.S. at 566.
152

See also Thompson v. W. Sts. Med. Ctr., 535 U.S. 357, 367 (2002) (explaining Central

Hudson does not apply if the speech concerns lawful activity and is not misleading); Central
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FDA’s prior thinking about a reasonable consumer.153 They would argue under this concept that
a single tweet demonstrating benefits and leaving either only the risks or a link to refer to them is
not inherently misleading.154 Based on the language from the guidance and existing case law,
the most applicable substantial government interest would be the protection of public health.155
In defense of this interest, the FDA would assert that the FDCA’s purpose is to protect public
health, that it should be afforded a “liberal construction,” and guidance is one of the informal
tools it has to perpetuate that purpose.156

Hudson, 447 U.S. at 563 (government may prohibit speech that is more likely to deceive the
public than inform it).
153

In a guidance document, the FDA entertained the “reasonable consumer standard.” The

standard looks through the eyes of a prospective consumer “acting reasonably in the
circumstances.” See U.S. FOOD & DRUG ADMIN., DRAFT GUIDANCE FOR INDUSTRY: PRESENTING
RISK INFORMATION IN PRESCRIPTION DRUG AND MEDICAL DEVICE PROMOTION 5 (2009)
[hereinafter PRESENTING RISK INFORMATION GUIDANCE].
154

Id.

155

See id. at 576 (finding a policy objective of public health to be “proper”); United States v.

Caronia, 703 F.3d 149, 166 (2d Cir. 2012) (finding that drug safety and public health are
substantial interests); see also CHARACTER LIMIT GUIDANCE, supra note 10, at 5 (stating the
public is best served through “truthful, non-misleading, and balanced” promotions).
156

See United States v. An Article of Drug . . . Bacto-Unidisk . . ., 394 U.S. 784, 798 (1969)

(stating that a court should give “effect” to the congressional intent in making the FDCA with an
“overriding purpose” of protecting the public health).
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Even if a reviewing court upheld this interest, the next big challenge is determining
whether the measure is drawn sufficiently.157 The guidance initially suggests that a firm seeking
to discuss benefits must also discuss the risks associated with the drug.158 It also permits a
manufacturer to use a link to expand upon the risks associated with the promoted drug, but it still
must include risks in the character limited message.159 The FDA would argue that disclosure of
information and a balanced presentation will best serve the public health.160 By requiring both a
showing of the risks and a link addressing them further, that objective is achieved. Further, they
would assert that they have left “open ample alternative channels for communication of
information” by allowing the risk discussion to continue elsewhere or simply allowing the firm
to choose an alternative advertising platform.161

157

In reviewing this element, the court is looking for a “fit between the legislature’s end and the

means chosen to accomplish those ends.” Sorrell, 564 U.S. at 572 (quoting Bd. of Trs. of St. U.
of N.Y. v. Fox, 492 U.S. 469, 480 (1989)).
158

CHARACTER LIMIT GUIDANCE, supra note 10, at 1.

159

Id. at 10.

160

See Va. St. Bd. of Pharm. v. Va. Citizens Consumer Council, Inc., 425 U.S. 748, 770 (1976)

(discussing people will make the best choices when they have the information available to them);
CHARACTER LIMIT GUIDANCE, supra note 10, at 5.
161

Va. St. Bd. of Pharm., 564 U.S. at 771.
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Conversely, industry would challenge that a listing of known risks and a link discussing
them further is imbalanced.162 Further, it would similarly argue that the public health might be
best served by simply only using a link for risk information because instead of a few words,
consumers might be more willing to view an entire landing page than a tweet alone for the drug
information.163 In doing so, they would contend under section 201(n) that they are revealing
material facts about a drug because the link provides the information and is textually related to
the article.164 Under statute and regulation, industry would also contend they are presenting
more than a fair balance of the risks because a character-limited post containing a brief statement
of benefit can be outweighed by a comprehensive discussion of the potential hazards under use
provided within a link.165 In terms of a less restrictive means, industry would likely assert that

162

See, e.g., PhRMA Letter, supra note 108, at 8–9 (stating that alternative means, such as using

“introductory phrases” and providing a link or using a “universal graphic[al] symbols” could
create a balanced presentation of information).
163

A reasonable consumer under the circumstances might not consider a single tweet as the

definitive authority on a drug’s information. See PRESENTING RISK INFORMATION GUIDANCE,
supra note 153, at 5 (articulating the standard for what a reasonable consumer does).
164

FDCA § 201(n), 21 U.S.C. § 321(n) (2018). This provision is also mentioned in the

background of the guidance as a place where the guidance draws its strength. CHARACTER LIMIT
GUIDANCE, supra note 10, at 3.
165

See FDCA § 502(n)(3), 21 U.S.C. § 352(n)(3) (advertisements or other descriptive matter

shall include information in brief summary pertaining to “side effects, contraindications, and
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the “One-Click Rule” is a less burdensome alternative than guidance suggestion of both risks and
a link, which could lead to the consequential decision of a firm “reconsider[ing]” use of the
platform.166 The question will hinge on whether the content within the link satisfies the fair
balance without the listing of the risks in the character-limited message.167
C. Off-Label Promotion Roadblocks
In a Second Circuit case, as the dissent puts it, “the majority calls into question the very
foundations of our century-old system of drug regulation.”168 In statements made to a
government informant, Mr. Caronia broadened the application of Xyrem beyond the contents of
the approved labeling.169 Unfortunately for the FDA, the majority found Sorrell’s application of
“heightened scrutiny” was warranted and the subsequent Central Hudson application yielded
negative results for the agency.170 The court found that the prohibitions on off-label promotion

effectiveness . . . .”); Prescription Drug Advertisements, 21 C.F.R. § 202.1(e)(5(ii) (2019)
(violation of this regulation will not be found when presentation of information is comparable).
166

CHARACTER LIMIT GUIDANCE, supra note 10, at 5. The “One-Click Rule” was an industry

developed initiative to provide a URL in a limited space to provide information instead of listing
it all out. See Randy Gray, Note, One Click is Enough: Satisfying FDA’s Fair Balance in the
Highly-Regulated Marketplace, 39 RUTGERS COMPUTER & TECH. L.J. 95, 103–4 (2013); West,
supra note 34, at 422.
167

CHARACTER LIMIT GUIDANCE, supra note 10, at 5.

168

United States v. Caronia, 704 F.3d 149, 169 (2d Cir. 2012) (Livingston, J., dissenting).

169

Id. at 156–57.

170

Id. at 164–69.
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were content-based.171 The court also ruled that the restrictions were speaker-based because they
targeted pharmaceutical manufacturers without restricting everyone else from discussing offlabel uses.172
Perhaps most critical to potential issues related to social media promotion, under Central
Hudson’s first element, the court found off-label promotion concerned lawful activity because
off-label drug use is legal.173 It also stated that off-label drug promotion is “not in and of itself
false or misleading.”174 While the FDA asserted the protection of the FDCA’s drug approval
process as a substantial interest, the court reasoned the FDA was overly burdensome.175
This problem for the FDA was further exacerbated a few years later with Amarin
Pharma, Inc. v. United States Food and Drug Administration.176 Here, the court rejected the
FDA’s argument that Caronia should be reviewed narrowly on its facts.177 Reemphasizing the
Caronia decision, the Amarin court stated the “considered and firm view is that, under Caronia,

171

Id. at 165.

172

Id.

173

Id. Drugs go through extensive testing to reach FDA approval status and to claim that off-

label discussion is lawful strikes an interesting counterbalance. See FDCA § 505(b)(1), 21
U.S.C. § 355(b)(1) (2018) (FDA drug approval requirements).
174

Caronia, 703 F.3d at 165.

175

Id. at 167–68 (reasoning the government could educate physicians to discern information or

develop a disclaimer system).
176

119 F. Supp. 3d 196 (S.D.N.Y. 2015).

177

Id. at 224.
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the FDA may not bring such an action based on truthful promotional speech alone, consistent
with the First Amendment.”178 The majority highlighted neither false nor misleading speech is
protected and that expression, but not conduct, is protected.179
This opinion highlights an integral challenge the FDA faces: protected expression.180
This makes the FDA’s regulatory job harder with respect to social media functions because
retweeting or sharing a post from a consumer in support of a product, even if the content is offlabel, will likely result in a comprehensive First Amendment analysis.181 While Amarin finds
that “Caronia leaves room for prosecuting off-label marketing as misbranding,” it still seems to
narrow the gap the FDA could prosecute by also stating “a manufacturer that engages in noncommunicative activities . . . cannot use the First Amendment as a shield.”182 A manufacturer
could raise that a post that is shared, retweeted, or liked is a communicative activity, and
therefore, behind a First Amendment shield.
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III. RECOMMENDATIONS
Social media is an evolving platform that shifts the way people and business can interact.
To some extent, there is a hidden genius to the FDA remaining silent on the subject for so long.
It could be the sole reason there has not been a proliferation of advertising for prescription drugs
on your Facebook page.183 However, industry will not remain idle as these sites and apps
become more attractive for reaching consumers.184 Facebook used to be just a place for people
to post their own thoughts and share articles or media. Now, it has a marketplace where
businesses and people can post goods and services they have for sale.185 These types of
technological evolutions in social media spaces might continue and business are attracted to it.186
The FDA should see this as an opportunity to update existing regulations and issue more
guidance in furtherance of its statutory calling. The following analyses will explore how the
FDA should consider social media functions in advertising and how this thinking could apply to
promulgating updated or new guidance issuances and rulemaking.
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A. Social Media Functions and Advertising
The FDA should directly address the functions of social media platforms to clarify the
regulatory gap that exists.187 To begin, it should invoke the FDCA and Kordel as authority over
such communications.188 It should continue to take an expansive view of the labeling provisions
because communications about an article ultimately supplement the article, which can
synchronously function as advertising information since the FDCA also addresses advertising in
a similar manner.189 For example, the FDA should indicate if a company “likes” or “retweets” a
statement about a product, that symbolic gesture should indicate the contents of the post
“accompany such article” consistent with the content of the affirmed post.190 This should be
seen as a “representation” of the product because it can evince an intent about a firm’s

187
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about the product); Kordel v. United States, 335 U.S. 345, 349 (1948) (finding that an article is
accompanied when something “supplements or explains it.”). See also PRESENTING RISK
INFORMATION GUIDANCE, supra note 153, n. 9 (defining “promotional piece, promotional
materials, and promotional communications” to include Internet web sites).
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understanding and beliefs about the product since it reaffirms one of its consumers endorsements
or other representations related to its use.191 If the post being “liked” or “retweeted” is in relation
to a use off-label, then a misbranding action could be brought against the firm.192
If the source of the firm’s engagement appears in a comment or user reply where
character limits are not a concern, then the FDCA and paired regulations provide the FDA with a
strong framework for regulating such representations.193 Under FDCA § 502(n)(3), for example,
the firm must provide the “brief summary” of the drug and if limits are of no concern, then the
inclusion of such should be required.194 These regulations should become more feasible because
in a space where one can place text and other media, without constraint, satisfying this
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requirement should be simple. Similar to the objectives of the third-party misinformation
guidance, a comment section provides opportunity to correct statements made about a product to
be consistent with the FDA approved labeling.195 Further, these limits provide firms the ability
to adequately clarify or specify important information, which can help shield from potential
misbranding violations that might arise from terse or unclear comments.196
The off-label promotion jurisprudence thus far does create some important concerns for
the FDA to monitor.197 Whereas Wisconsin v. Mitchell held the “First Amendment . . . does not
prohibit the evidentiary use of speech to establish elements of a crime,” Caronia offered stark
contrast, instead, prohibiting the FDA from doing as such.198 The best hope for the FDA in this
dichotomy is that the Supreme Court rejects Caronia or at least the Second Circuit overrules
itself with other circuits declining to accept the holding. However, a trend seems to indicate
whenever the means by which the government seeks to achieve its substantial interest in the
sphere of drug regulation, the reviewing court finds less restrictive means that could be
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employed, or an exception is carved out.199 These precedents seem to have eroded the
government’s capacity to win on the first element of Central Hudson.200
Nonetheless, the FDA should incorporate a direct discussion about how social media
functions can lead to a drug becoming misbranded.201 Since social media provides the ability to
use differing forms of media, this can create a diverse array of options for which the FDA can
evaluate claims made by a company.202 An example could be for video mediums, like Snapchat,
advertising videos that illustrate someone using a drug for an indication unapproved by the FDA
could be grounds for a misbranding action, especially if the post also provides a link to
information unsupported by the FDA labeling.203 If a firm repeatedly likes and shares customer
testimonials, without influencing or soliciting the information, then the FDA might find the
product as a “new drug” that, unsupported by an approved FDA application, is illegal.204
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B. Issuing Further and Updated Guidance Documents
The FDA should update or issue final guidance on the presently titled social media
guidance documents. Six years of public availability should present a reasonable window of
time to update existing thinking. Industry has shared its perspective on the guidance documents
and found several problems.205 First Amendment issues, especially Sorrell, were a major source
of concern over the character limit guidance.206 Since the FDA failed to address the First
Amendment in its current thinking, it should update existing guidance to include a discussion of
this. Central Hudson and Sorrell should be the focus since they lay the foundation for review.207
For the third-party misinformation guidance, the FDA should permit the corrective
material to be promotional in nature. This serves the purpose of becoming less-restrictive than
necessary and would give creative latitude to manufacturers to send corrective information using
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advertisements containing either the major statement or brief summary for the prescription drug
that needs its information corrected in a medium.208
In taking the path to update the character limit guidance, it should consider adopting lessrestrictive means and include the First Amendment jurisprudence. For instance, it should
consider lightening up the suggestion that a firm incorporate both important risks and a URL to
address them further.209 Industry offers a good suggestion for the adoption of universal
iconography, which could make research easier on the consumer.210 It could pair this with the
creation of its own education materials for consumers to teach them the important aspects of
drug labeling and advertising and what to look for.211 This will serve an important purpose for
the First Amendment jurisprudence because the courts have continued to find ways the
government could be less restrictive when creating burdens on speech.212 To address this case,
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the FDA should continue to explain that the public health is the core of its rationale for providing
such guidance.213 If it is going to suggest a firm not use a particular platform due to inability to
meet the “fair balance” requirement, it should afford thinking as to why the suggested
prohibition is permissible and give explanation to alternative means for the firm to use.214 In
doing so, the FDA would take into account both Sorrell and Central Hudson by explaining the
measures taken are “not more extensive than necessary” to achieve the protection of the public
health.215 The use of a link in addition to the risk information poses one of the places for
elaborating on this thinking.216 In addition to how character-limited spaces might impact a
consumer becoming misled, the guidance should incorporate consumer studies to help provide
further guidance and context for what factors most directly contribute to consumer
understandings.217
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The FDA should take this as an opportunity to provide new and direct guidance about
how it believes user interactions will fall within the scope of the FDCA. For example, new
guidance could explain that liking posts about a product creates a “textual relationship” that can
be considered reviewed in a misbranding action.218 Videos that can reach the same length as
other broadcast mediums can also fall under the same guidelines imposed on those mediums.219
New guidance could also address how DTC advertising and using targeted advertising tools on
social media could be regulated.220 For instance, the FDA explore how demographic tools
among other factors could lead to a drug becoming misbranded because the promotion of such
drug is “false or misleading” because the targeted group of individuals is not within the scope of
the FDA approved labeling.221 It could also directly address First Amendment jurisprudence
because the first element of Central Hudson does not protect speech that is not truthful or
misleading.222

also meet potential legal hurdles related to a court determining if the language is definitively
misleading. See FDCA § 201(n), 21 U.S.C. § 321(n) (2018); Central Hudson, 447 U.S. at 563
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Additionally, this creates a prime opportunity to obtain comments on its statutory and
case law interpretations. In the wake of either new or updated guidance, this is a chance for
government and industry to come together and grapple with these developing platforms. The
FDA should consider reaching out to the creators of these platforms to gather developer insights
for what these social media platforms can achieve in order to create effective rules or guidance
that can address a lasting and evolving system. Like the growth of radio and television, which
have run alongside print, this new medium seems to combine the two and the FDA should not
continue to let it grow without documenting some form of updated thinking.
C. Notice-and-Comment Rulemaking
Notice-and-comment rulemaking could be a more effective tool to promulgate new
regulations for governing social media tools. The APA provides agencies the ability to create
“rules” in furtherance of their statutory calling.223 Unlike the guidance exemption, this route also
provides something that guidance documents do not: a rule with a force of law.224 However, the
agency must adhere to several formalities.225 Summarily, an agency must provide the public
with an opportunity to comment on a proposed rule and consider such comments in promulgation
of the final rule.226

223

A “rule” under the APA means “the whole or a part of an agency statement of general or

particular applicability and future effect designed to implement, interpret, or prescribe law or
policy . . . .” APA, 5 U.S.C. § 551(4) (2018) (emphasis added).
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In using this method to address social media functionality, the FDA should update
existing regulations to include social media and digital advertising. As an example, in the
“Prescription Drug Advertisements” regulation, the current provision of the act provides
“Advertisements subject to section 502(n) of the act include advertisements in published
journals, magazines, other periodicals, and newspapers, and advertisements broadcast through
media such as radio, television, and telephone communication systems.”227 The FDA should
address this section of the CFR to include digital platforms and include language that names
social media as an example. Another opportunity for update comes in the next subsection, which
lists different types of descriptive matter the FDA deems to be “labeling” under the FDCA.228
While it comes close to identifying digital and social media items with “similar pieces of printed,
audio, or visual matter descriptive of a drug,” it could stand to benefit from a clearer definition
that “similar pieces” include digital advertisements and labeling of the drug.229
The usage of notice-and-comment rulemaking has several benefits for the FDA and
industry. One such advantage is the public process for issuing comments.230 By utilizing this
process, the FDA can obtain documented feedback for its current vacuum in social media
regulation by reviewing how industry believes the agency can proceed. Another advantage to
this process is that social media platforms could also provide comments and information about

227
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how their platform could contribute to the success of the FDA’s progress in creating effective
policy.231 This highly visible public process encourages accountability, which was fundamental
in the passage of the APA.232 In the public sphere, industry benefits from this accountability
because the FDA must consider its comments.233 The FDA wins from this accountability
because it gets a second-mover advantage of receiving this feedback and earning the opportunity
to consider and craft around the major concerns offered by the public.234 However, significant
challenges exist, like the costs associated with crafting, publicizing, and finalizing review of a
proposed rule.235 Further, input by individuals who are not directly regulated by agency rules
may not provide input, leading the agency to bend toward only the regulated interest and not the
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public at-large.236 Despite these costs, the ability to create a regulation with the force of law
provides significant value in furthering the agency’s statutory calling.237
CONCLUSION
The advent of social media has proliferated and amalgamized itself to be a massive force
in the future of the digital age.238 Digital advertising expenditures by the pharmaceutical
industry demonstrates a financial testament to the importance of advertising.239 With a drug
approval process that is both rigorous and expensive, companies finding more attractive ways to
promote products will remain a priority.240 By adhering to statutory provisions and updating
existing regulations and thinking on the topic, the FDA will be able to successfully create and
enforce guidelines designed to promote the public health. By doing so, the FDA will make
significant headway in the rapidly developing digital age. In promulgating these regulations or
issuing guidance documents, the FDA should make the concerted effort to address existing First
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Amendment issues that have begun proliferating.241 By implementing an approach that
demonstrates it is not trying to be unduly burdensome, the FDA should be able to place itself in a
position to thwart challenges while still implementing effective new policies in prescription drug
advertising regulations.242
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